Literature DB >> 21569005

Evidence for a macromolecular complex in poor prognosis CLL that contains CD38, CD49d, CD44 and MMP-9.

Andrea G S Buggins1, Ana Levi, Satyen Gohil, Keith Fishlock, Piers E M Patten, Yolanda Calle, Deborah Yallop, Stephen Devereux.   

Abstract

Progressive chronic lymphocytic leukaemia is characterized by the accumulation of neoplastic B-cells in the tissues and correlates with the expression of prognostic biomarkers, such as CD38, CD49d and matrix metalloproteinase-9 (MMP9), which are involved in migration and tissue invasion. In this study we investigated the physical relationship between these molecules and demonstrated that CD38, CD49d, MMP9 and CD44 were physically associated in a supramolecular cell surface complex. Our findings provide a molecular basis for the correlation between expression of these proteins and prognosis and, as the complex is not present in normal B-cells, suggest a novel leukaemia-specific therapeutic target.
© 2011 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21569005     DOI: 10.1111/j.1365-2141.2011.08725.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  28 in total

1.  The Human CD38 Monoclonal Antibody Daratumumab Shows Antitumor Activity and Hampers Leukemia-Microenvironment Interactions in Chronic Lymphocytic Leukemia.

Authors:  Alba Matas-Céspedes; Anna Vidal-Crespo; Vanina Rodriguez; Neus Villamor; Julio Delgado; Eva Giné; Heleia Roca-Ho; Pablo Menéndez; Elías Campo; Armando López-Guillermo; Dolors Colomer; Gaël Roué; Adrian Wiestner; Paul W H I Parren; Parul Doshi; Jeroen Lammerts van Bueren; Patricia Pérez-Galán
Journal:  Clin Cancer Res       Date:  2016-09-16       Impact factor: 12.531

2.  α4β1 integrin associates with VEGFR2 in CLL cells and contributes to VEGF binding and intracellular signaling.

Authors:  Alejandra Gutiérrez-González; Noemí Aguilera-Montilla; Estefanía Ugarte-Berzal; Elvira Bailón; Isabel Cerro-Pardo; Clara Sánchez-Maroto; Lara García-Campillo; José A García-Marco; Angeles García-Pardo
Journal:  Blood Adv       Date:  2019-07-23

3.  Bone marrow stromal cells protect lymphoma B-cells from rituximab-induced apoptosis and targeting integrin α-4-β-1 (VLA-4) with natalizumab can overcome this resistance.

Authors:  Marek Mraz; Clive S Zent; Amy K Church; Diane F Jelinek; Xiaosheng Wu; Sarka Pospisilova; Stephen M Ansell; Anne J Novak; Neil E Kay; Thomas E Witzig; Grzegorz S Nowakowski
Journal:  Br J Haematol       Date:  2011-07-12       Impact factor: 6.998

4.  Calcium-RasGRP2-Rap1 signaling mediates CD38-induced migration of chronic lymphocytic leukemia cells.

Authors:  Silvia Mele; Stephen Devereux; Andrea G Pepper; Elvira Infante; Anne J Ridley
Journal:  Blood Adv       Date:  2018-07-10

Review 5.  CD38 and chronic lymphocytic leukemia: a decade later.

Authors:  Fabio Malavasi; Silvia Deaglio; Rajendra Damle; Giovanna Cutrona; Manlio Ferrarini; Nicholas Chiorazzi
Journal:  Blood       Date:  2011-07-15       Impact factor: 22.113

Review 6.  The progress of angiogenic factors in the development of leukemias.

Authors:  Yang Han; Xidi Wang; Bingping Wang; Guosheng Jiang
Journal:  Intractable Rare Dis Res       Date:  2016-02

7.  The γ-secretase inhibitor PF-03084014 combined with fludarabine antagonizes migration, invasion and angiogenesis in NOTCH1-mutated CLL cells.

Authors:  M López-Guerra; S Xargay-Torrent; L Rosich; A Montraveta; J Roldán; A Matas-Céspedes; N Villamor; M Aymerich; C López-Otín; P Pérez-Galán; G Roué; E Campo; D Colomer
Journal:  Leukemia       Date:  2014-04-30       Impact factor: 11.528

8.  Targeting chronic lymphocytic leukemia cells with a humanized monoclonal antibody specific for CD44.

Authors:  Suping Zhang; Christina C N Wu; Jessie-F Fecteau; Bing Cui; Liguang Chen; Ling Zhang; Rongrong Wu; Laura Rassenti; Fitzgerald Lao; Stefan Weigand; Thomas J Kipps
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-25       Impact factor: 11.205

9.  SLAMF1 regulation of chemotaxis and autophagy determines CLL patient response.

Authors:  Cinzia Bologna; Roberta Buonincontri; Sara Serra; Tiziana Vaisitti; Valentina Audrito; Davide Brusa; Andrea Pagnani; Marta Coscia; Giovanni D'Arena; Elisabetta Mereu; Roberto Piva; Richard R Furman; Davide Rossi; Gianluca Gaidano; Cox Terhorst; Silvia Deaglio
Journal:  J Clin Invest       Date:  2015-11-30       Impact factor: 14.808

Review 10.  The pathogenesis of chronic lymphocytic leukemia.

Authors:  Suping Zhang; Thomas J Kipps
Journal:  Annu Rev Pathol       Date:  2013-08-26       Impact factor: 23.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.